Veeva Systems (NYSE:VEEV) Given New $212.00 Price Target at Stifel Nicolaus

Veeva Systems (NYSE:VEEV) had its price target decreased by Stifel Nicolaus from $320.00 to $212.00 in a research note issued to investors on Thursday morning,Benzinga reports. Stifel Nicolaus currently has a buy rating on the technology company’s stock.

VEEV has been the subject of several other research reports. KeyCorp restated a “sector weight” rating on shares of Veeva Systems in a research note on Friday, December 12th. Morgan Stanley raised Veeva Systems from an “underweight” rating to an “equal weight” rating and reduced their target price for the company from $222.00 to $205.00 in a research note on Tuesday, February 17th. Weiss Ratings lowered shares of Veeva Systems from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 12th. Needham & Company LLC restated a “buy” rating and set a $355.00 target price on shares of Veeva Systems in a report on Friday, November 21st. Finally, Wells Fargo & Company dropped their price target on shares of Veeva Systems from $341.00 to $333.00 and set an “overweight” rating for the company in a research report on Tuesday, November 25th. Eighteen research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $293.71.

Veeva Systems Price Performance

VEEV opened at $182.84 on Thursday. Veeva Systems has a fifty-two week low of $168.13 and a fifty-two week high of $310.50. The firm has a market capitalization of $30.06 billion, a P/E ratio of 35.57, a PEG ratio of 1.22 and a beta of 1.08. The company’s 50-day moving average is $207.69 and its 200 day moving average is $251.18.

Veeva Systems announced that its Board of Directors has approved a stock repurchase plan on Monday, January 5th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the technology company to repurchase up to 5.5% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.

Insider Activity

In other Veeva Systems news, insider Thomas D. Schwenger sold 1,000 shares of the business’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $231.43, for a total transaction of $231,430.00. Following the completion of the sale, the insider directly owned 23,204 shares in the company, valued at approximately $5,370,101.72. The trade was a 4.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.30% of the stock is currently owned by insiders.

Institutional Trading of Veeva Systems

Hedge funds have recently bought and sold shares of the stock. GPS Wealth Strategies Group LLC grew its position in shares of Veeva Systems by 196.4% during the third quarter. GPS Wealth Strategies Group LLC now owns 83 shares of the technology company’s stock worth $25,000 after purchasing an additional 55 shares in the last quarter. Board of the Pension Protection Fund bought a new stake in shares of Veeva Systems in the fourth quarter worth about $27,000. Raiffeisen Bank International AG purchased a new stake in shares of Veeva Systems in the third quarter worth about $28,000. Newbridge Financial Services Group Inc. lifted its position in shares of Veeva Systems by 322.6% in the fourth quarter. Newbridge Financial Services Group Inc. now owns 131 shares of the technology company’s stock worth $29,000 after buying an additional 100 shares in the last quarter. Finally, Activest Wealth Management boosted its stake in Veeva Systems by 3,175.0% during the fourth quarter. Activest Wealth Management now owns 131 shares of the technology company’s stock valued at $29,000 after buying an additional 127 shares during the last quarter. Institutional investors own 88.20% of the company’s stock.

More Veeva Systems News

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Company authorized a new ~US$2 billion share buyback and analysts have recently revised some estimates upward, supporting renewed investor focus on valuation and capital return. This buyback is being cited as a main catalyst for renewed demand. A Look At Veeva Systems (VEEV) Valuation
• Positive Sentiment: Veeva launched “eSource” to streamline clinical-trial data capture — a product extension that can expand stickiness with life-sciences customers and support subscription revenue growth. Product launches that improve workflow integration are generally positive for recurring SaaS sales. Veeva Systems Inc. (VEEV) Launches eSource
• Positive Sentiment: Market headlines and broad sector flows have highlighted Veeva as a top mover today, helping momentum-driven buying. General coverage pointing to the stock “skyrocketing” has likely amplified intraday demand. Veeva Systems, Upstart, Paycom, Commvault, and Agilysys shares skyrocket
• Neutral Sentiment: Stifel trimmed its price target (from $320 to $212) but retained a Buy rating, signaling mixed analyst sentiment: lower upside expectations but continued buy-side endorsement. Stifel price target change
• Neutral Sentiment: Coverage pieces (Zacks, recent market summaries) note Veeva as a trending name — raising attention but not changing fundamentals by itself. Veeva trending stock note
• Negative Sentiment: Multiple broker price targets were lowered recently (Barclays, Oppenheimer among them), reflecting more cautious medium-term estimates even as most maintain constructive ratings — a headwind for valuation. Barclays price target note Oppenheimer lowers price target
• Negative Sentiment: Short interest rose ~26% in February to roughly 6.33M shares (about 4.3% of float), increasing bearish pressure and potential volatility should sentiment change. (Data reported Feb 13.)

Veeva Systems Company Profile

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.